KLK3 and prostate carcinoma: For patients with 1-PSA < 4.0 ng/mL, an increase in 2-PSA of 18% or more over 1-PSA was associated with a significantly increased risk of developing prostate cancer compared with the group with no PSA variation (Table 3).